Skip to content
Medical Health Aged Care, Science

New gene discoveries improve diagnosis of inherited heart disease

Centenary Institute 2 mins read

Centenary Institute researchers have uncovered new genetic causes of inherited heart conditions, providing families with vital answers to guide treatment and prevention.

 

Inherited heart conditions affect more than one in every 200 Australians and are a major cause of illness and premature death.

 

The study, published in Genetics in Medicine, re-examined data from the Australian Genomics Cardiovascular Disorders Flagship, a national program that originally sequenced the genetic material of more than 500 Australians living with cardiomyopathy (heart muscle disease) or primary arrhythmia syndromes (abnormal heart rhythms).

 

The research team applied updated analysis methods, examined a broader range of heart-related genes and ran advanced laboratory tests to check the impact of uncertain DNA variations in the genomic dataset. With this deeper investigation, they were able to give an extra 4% of participants a confirmed genetic diagnosis that earlier testing had missed.

 

“Each additional diagnosis has a direct and tangible impact,” said Associate Professor Richard Bagnall, Head of the Centre for Cardiovascular Research at the Centenary Institute and senior author of the study.

 

“It explains why a person developed heart disease, informs their treatment and can guide genetic screening for relatives who may also be at risk.”

 

The study also confirmed a new disease-causing gene (TBX20) for cardiomyopathy that had previously been omitted in standard testing.

 

“These results show us that the genetic basis of heart disease is broader and more complex than we once thought,” said Yuchen Chang, PhD candidate at the University of Sydney and the Centenary Institute, and first author of the study.

 

“By continually updating gene panels (checklists of genes linked to specific heart conditions) and validating uncertain results in the laboratory, we can improve diagnosis rates and deepen our understanding of these conditions.”

 

The researchers say that re-analysing genomic data with the latest tools and knowledge will continue to improve genetic diagnosis for inherited heart conditions. This means more families can receive timely answers, clinicians can tailor care more effectively and new discoveries can be more quickly put into practice to benefit patients.

 

[ENDS]

 

Publication: Increased yield of genetic diagnoses in inherited heart diseases using expanded genome and RNA-splicing analyses

https://www.sciencedirect.com/science/article/pii/S1098360025002734


About us:

About the Centenary Institute

The Centenary Institute is a world-leading independent medical research institute, closely affiliated to the University of Sydney and the Royal Prince Alfred Hospital. Our research spans the critical areas of cancer, cardiovascular disease, rare diseases, inflammation, infectious diseases, healthy ageing and biomedical AI. Our strength lies in uncovering disease mechanisms and applying this knowledge to improve diagnostics and treatments for patients.

For more information about the Centenary Institute, visit centenary.org.au


Contact details:

For all media and interview enquiries, please contact

Tony Crawshaw, Media and Communications Manager, Centenary Institute on 0402 770 403 or email: [email protected]

More from this category

  • Medical Health Aged Care
  • 07/12/2025
  • 01:41
Takeda Pharmaceutical Company Limited

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline NEWARK,…

  • Medical Health Aged Care
  • 06/12/2025
  • 02:11
Arthur D. Little

Arthur D. Little and Vega IT Unveil Joint Venture for Digital Innovation

NEW YORK–BUSINESS WIRE– Arthur D. Little (ADL) and Vega IT today announced the formation of Axceler8 Solutions, a 50/50 joint venture created to design,…

  • Contains:
  • Science
  • 05/12/2025
  • 11:11
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance

BEIJING–BUSINESS WIRE– Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.